Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Stallard

Showing results (31-40 of 153) with videos related to

Pageof 16
Sort By:
European Journal of Public Health|January 19, 2008
Parenting and health in mid-childhood: a longitudinal studyAndrea Waylen, Nigel Stallard, Sarah Stewart-Brown
Biometrical Journal. Biometrische Zeitschrift|November 1, 2013
A comparison of methods for constructing confidence intervals after phase II/III clinical trialsPeter K Kimani, Susan Todd, Nigel Stallard
Statistics in Medicine|September 28, 2018
An alternative method to analyse the biomarker-strategy designCornelia Ursula Kunz, Thomas Jaki, Nigel Stallard
Journal of Biopharmaceutical Statistics|July 19, 2005
An adaptive group sequential design for phase II/III clinical trials that select a single treatment from severalPatrick J Kelly, Nigel Stallard, Susan Todd
Biometrical Journal. Biometrische Zeitschrift|July 27, 2017
Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distributionSiew Wan Hee, Nicholas Parsons, Nigel Stallard
Orphanet Journal of Rare Diseases|June 16, 2016
Directions for new developments on statistical design and analysis of small population group trialsRalf-Dieter Hilgers, Kit Roes, Nigel Stallard, et al.
BMC Medical Research Methodology|February 16, 2024
Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementationNick R Parsons, Joydeep Basu, Nigel Stallard
Statistics in Medicine|March 27, 2013
Planning multi-arm screening studies within the context of a drug development programJames M S Wason, Thomas Jaki, Nigel Stallard
Pharmaceutical Statistics|September 2, 2022
Should the two-trial paradigm still be the gold standard in drug assessment?Stella Jinran Zhan, Cornelia Ursula Kunz, Nigel Stallard
Statistics in Medicine|February 12, 2005
Statistical design and analysis of pharmacogenetic trialsPatrick J Kelly, Nigel Stallard, John C Whittaker
Pageof 16

Showing results (31-40 of 153) with videos related to

Sort By:
Pageof 16
European Journal of Public Health|January 19, 2008
Parenting and health in mid-childhood: a longitudinal studyAndrea Waylen, Nigel Stallard, Sarah Stewart-Brown
Biometrical Journal. Biometrische Zeitschrift|November 1, 2013
A comparison of methods for constructing confidence intervals after phase II/III clinical trialsPeter K Kimani, Susan Todd, Nigel Stallard
Statistics in Medicine|September 28, 2018
An alternative method to analyse the biomarker-strategy designCornelia Ursula Kunz, Thomas Jaki, Nigel Stallard
Journal of Biopharmaceutical Statistics|July 19, 2005
An adaptive group sequential design for phase II/III clinical trials that select a single treatment from severalPatrick J Kelly, Nigel Stallard, Susan Todd
Biometrical Journal. Biometrische Zeitschrift|July 27, 2017
Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distributionSiew Wan Hee, Nicholas Parsons, Nigel Stallard
Orphanet Journal of Rare Diseases|June 16, 2016
Directions for new developments on statistical design and analysis of small population group trialsRalf-Dieter Hilgers, Kit Roes, Nigel Stallard, et al.
BMC Medical Research Methodology|February 16, 2024
Group sequential designs for pragmatic clinical trials with early outcomes: methods and guidance for planning and implementationNick R Parsons, Joydeep Basu, Nigel Stallard
Statistics in Medicine|March 27, 2013
Planning multi-arm screening studies within the context of a drug development programJames M S Wason, Thomas Jaki, Nigel Stallard
Pharmaceutical Statistics|September 2, 2022
Should the two-trial paradigm still be the gold standard in drug assessment?Stella Jinran Zhan, Cornelia Ursula Kunz, Nigel Stallard
Statistics in Medicine|February 12, 2005
Statistical design and analysis of pharmacogenetic trialsPatrick J Kelly, Nigel Stallard, John C Whittaker
Pageof 16